Premium
From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs
Author(s) -
Carden CP,
Banerji U,
Kaye SB,
Workman P,
Bono JS
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.223
Subject(s) - clinical trial , clinical pharmacology , drug , drug development , medicine , oncology , cancer , pharmacology , bioinformatics , biology
Compared with conventional chemotherapy, rationally designed molecularly targeted agents may be more likely to have antitumor activity in selected tumor subgroups driven by the oncogenic signals targeted by these compounds and a different side‐effect profile. The use of biomarkers in the early clinical trials of these new anticancer agents has the potential to increase study participants’ benefit from early clinical trials, accelerate the drug development process, maximize the ability to generate important biological information about human cancer, and decrease the risk of late and costly drug attrition. Clinical Pharmacology & Therapeutics (2009); 85 , 2, 131–133 doi: 10.1038/clpt.2008.223